PBAC Submission of Galafold™ (migalastat) for Fabry disease
25 Aug 2017 at 12:00AM
Category: Fabry Australia News
Following on from the recent news that the Australian
Therapeutic Goods Administration (TGA) approve Galafold™ (migalastat) for the
treatment of Fabry Disease. Refer to Fabry
Australia’s public statement.
The Pharmaceutical Benefits Advisory Committee (PBAC) are
considering Galafold™ (migalastat) for the treatment of Fabry Disease for
listing as a new medicine in Australia as part of its agenda for the next PBAC
meeting which will be held in November 2017. You can help! The public (including Fabry patients/ families/ friends / doctors) are invited to provide
feedback via an online submission.
Press the following link to complete the online form and for further information on how to complete your submission; http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form
The closing date for community feedback is 4
For further information and details contact Fabry Australia